Biggest News Aggregation in the World
📰 Potential Uses News

Page 3 - Potential Uses News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Potential Uses. Real-time updates on events, politics, business and more.

Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study evaluating the BCMAxCD3 bispecific antibody, including progression-free survival and subgroup analyses1Data from MajesTEC-1 study published in The New England Journal of Medicine2BEERSE, Belgium--(B...
United States Jenni Mildon Yusri Elsayed Edmond Chan Mbch Maria Victoria Mateos None Of The Janssen Pharmaceutical Companies

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

European Commission Grants Conditional Approval of CARVYKTI (Ciltacabtagene Autoleucel), Janssen's First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients
United States Ciltacabtagene Autoleucel Jenni Mildon Maria Victoria Mateos Sen Zhuang Edmond Chan

Janssen Receives Positive CHMP Opinion Recommending CARVYKTI (Ciltacabtagene Autoleucel) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Ciltacabtagene autoleucel (cilta-cel), Janssen's first cell therapy, is a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies The Janssen Pharmaceutical Companies of Johnson
United States Ciltacabtagene Autoleucel Jenni Mildon Edmond Chan Mbch Sen Zhuang American Society Of Clinical Oncology

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science